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8 ABSTRACT: Glycogen phosphorylase inhibitors are consid-
9 ered as potential antidiabetic agents. 3-(β-D-Glucopyranosyl)-
10 5-substituted-1,2,4-triazoles were prepared by acylation of O-
11 perbenzoylated N1-tosyl-C-β-D-glucopyranosyl formamidrazone and subsequent removal of the protecting groups. The best
12 inhibitor was 3-(β-D-glucopyranosyl)-5-(2-naphthyl)-1,2,4-triazole (Ki = 0.41 μM against rabbit muscle glycogen phosphorylase
13 b).
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15 Inhibitors of enzymes are among classics of medicinal16 chemistry, and many drug molecules’ activity is due to
17 decreasing the eﬃciency of these catalytic proteins.1 In a
18 chemical biological approach, ﬁnding an enzyme inhibitor is the
19 result of a good match of the biological and chemical spaces
20 represented by a binding site of an enzyme and a small
21 molecule, respectively, ﬁtting to each other with considerable
22 strength. Among several methods to design inhibitors,
23 bioisosteric replacement of structural elements of existing
24 molecules is widely applied and in many cases results in higher
25 activity or other advantageous property of the new compound.2
26 Glycogen phosphorylase (GP) is the main regulatory enzyme
27 of glycogen metabolism. GP, catalyzing the rate determining
28 step of glycogen degradation in the liver by phosphorolysis, is
29 directly responsible for the regulation of blood glucose levels.
30 Therefore, GP has been a validated target in combating
31 noninsulin-dependent or type 2 diabetes mellitus (T2DM), and
32 its inhibitors are considered as potential antidiabetic agents.
33 The biochemical and pharmacological background of this
34 research has been thoroughly summarized in several reviews of
35 the past decade; therefore, the reader is kindly referred to those
36 papers.3−5 Furthermore, possible application of GP inhibitors
37 in intervention of other diseased states associated with GP
38 activity (e.g., cardiovascular disorders,6 ischemic lesions,7,8 and
39 tumorous growth7) has also been under investigations.
40 Several classes of compounds9,10 were shown to be inhibitors
41 of GP. The most widely studied group of molecules is that of
42 glucose derivatives,11,12 which bind primarily to the active site
43 of GP.13 The best glucose derivatives are submicromolar
44 inhibitors of rabbit muscle GPb, the prototype of GPs.14
45 Glucopyranosylidene-spiro-thiohydantoin (Ki = 29.8 μM
46 against rat liver GP) was shown to exert considerable in vivo
47 blood sugar diminishing activity.15
c1 48 N-Acyl-β-D-glucopyranosylamines (compounds 1 in Chart 1)
49 were among the ﬁrst GP inhibitors,16 and many analogous
50 derivatives were investigated.17−20 In this series, N-(2-
51naphthoyl)-β-D-glucopyranosylamine (1 R = 2-naphthyl) was
52the best inhibitor,18 which also served as a lead structure for
53bioisosteric replacements. As illustrated in Chart 1, enzymatic
54tests21 as well as crystallographic studies19 revealed high
55similarity of amide (1) and 1,2,3-triazole (2) type inhibitors
56both in binding strength and structural features of the enzyme−
57inhibitor complexes. Kinetic tests of bioisosteric oxadiazoles22,23
583−5 demonstrated that the constitution of the heterocycle had
59a strong bearing on the inhibition: the most eﬃcient inhibitor
60in these series was 5-(β-D-glucopyranosyl)-3-(2-naphthyl)-
611,2,4-oxadiazole (5), which had a similar eﬃciency to that of 1.
62Other investigations on C-glucopyranosyl heterocycles with
63condensed rings showed that benzothiazole 7 was much less
64eﬃcient than benzimidazole 8.24 An X-ray crystallographic
65study of the RMGPb−8 complex revealed a speciﬁc H-bond
66between NH of the heterocycle and the main chain CO of
67His377,25 and the stronger binding of 8 was attributed to this
68interaction, which cannot exist in the case of 7.
69On the basis of these preliminaries, synthesis and study of
701,2,4-triazoles of type 6 were envisaged anticipating that the H-
71bond donor capacity of this heterocycle would result in
72stronger inhibitors of GP.
733-Glycosyl-5-substituted-1,2,4-triazoles were described in the
74literature mainly with furanoid rings in reactions of C-
75glycofuranosyl (thio)formimidates with hydrazide or amidra-
76zone reagents26−28 or transforming a 2,5-anhydro-D,L-allono-
77lactone derivative with aminoguanidine.29 3-Glycopyranosyl-5-
78substituted-1,2,4-triazoles could not be located in the literature;
79the only C-glycopyranosyl-1,2,4-triazoles were 1,3,5-trisubsti-
80tuted derivatives obtained from glycosyl cyanides with 1-aza-2-
81azoniaallene salts30 or with hydrazonoyl chlorides in the
82presence of Yb(OTf)3.
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83 Synthesis of the desired 3-glucopyranosyl-5-substituted-1,2,4-
84 triazoles of type 6 was planned by adaptation of a literature
85 protocol32 in which acylation of N1-tosylamidrazones gave 3,5-
86 disubstituted-1-tosyl-1,2,4-triazoles. Removal of the N-tosyl
87 group was foreseen under conditions usually applied for N-
88 desulfonylation of nitrogen heterocycles.33
89 To start the syntheses, O-perbenzoylated β-D-glucopyranosyl
90 formimidate34 9 was reacted with tosylhydrazide to give the
s1 91 necessary tosylamidrazone 10 in good yield (Scheme 1).
92 Reaction of 10 with acetyl chloride furnished tosyl-triazole 11a,
93 which was N-detosylated by tetrabutylammonium ﬂuoride
94 (TBAF) to 12a. With acetoxyacetyl chloride 10 gave a mixture
95 of 11b and 12b indicating that the N-tosyl group is prone to
96 splitting oﬀ under the acylation conditions. The crude mixture
97 of 11b and 12b was treated with TBAF to produce 12b in 61%
98 yield for the two steps. Acylations of 10 with aromatic acid
99 chlorides were accompanied by complete N-detosylation
100 thereby simplifying the preparation of 12d−f, which were
101 obtained in good yields. Removal of the O-acyl protecting
102 groups was eﬀected under Zempleń conditions to give test
103 compounds 6a and 6c−f in good to excellent yields.
1043-(β-D-Glucopyranosyl)-5-substituted-1,2,4-triazoles 6 were
105assayed against RMGPb as described earlier,35 and the kinetic
106results, showing the compounds to be competitive inhibitors,
107 t1are summarized in Table 1. Methyl (6a) and hydroxymethyl
108(6c) derivatives proved weak inhibitors in the micromolar
109range and were signiﬁcantly less eﬃcient than the parent
110amides 1a and 1c, respectively. Appending unsubstituted
111aromatic groups to the 1,2,4-triazole ring as in 6d and 6f led
Chart 1. Selected Inhibitors of Glycogen Phosphorylase and
Their Eﬃciencya
aKi [μM] against RMGPb for R = 2-naphthyl.
bA Ki value of 2.4 μM
was measured independently by Oikonomakos and co-workers.22
Scheme 1. Synthesis of 3-(β-D-Glucopyranosyl)-5-
substituted-1,2,4-triazoles (6)
Table 1. Inhibitiona of RMGPb by Compounds 6 and
Comparison to Other Nonclassical Bioisosteres
aKi [μM]
bCalculated from the IC50 value by using a web-based tool.
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112 to a remarkable strengthening of the inhibition. While 1,2,4-
113 oxadiazoles 5d and 5f were practically equipotent with the
114 corresponding amides 1d and 1f, triazoles 6d and 6f inhibited
115 the enzyme by ∼1 order of magnitude stronger, respectively.
116 This indicated that the possibility for the formation of a H-
117 bond was advantageous for the binding, rendering compound
118 6f to one of the most eﬃcient glucose analogue inhibitors of
119 GP known to date. Introduction of a t-butyl substituent in the
120 4-position of the phenyl group as in 6e resulted in a much
121 weaker inhibitor. This observation may reveal that the active
122 site of GP, where these compounds may bind to, can not
123 accommodate a bulky aliphatic moiety.
124 Further studies to establish the binding peculiarities of these
125 inhibitors by X-ray crystallographic investigation of the
126 enzyme−inhibitor complexes as well as molecular dockings to
127 predict other eﬃcient derivatives based on this skeleton are in
128 progress.
129 In conclusion, a new method was elaborated for the synthesis
130 of hitherto unknown 3-(β-D-glucopyranosyl)-5-substituted-
131 1,2,4-triazoles. These compounds inhibited rabbit muscle
132 GPb, and the 5-(2-naphthyl) derivative with its submicromolar
133 inhibition proved one of the best inhibitors of the enzyme.
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